Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Hydrophobic Mesh Slows Drug Release

Air displacement controls water flow through a hydrophobic polymeric material, enabling extended release of an anticancer drug

by Elizabeth K. Wilson
February 6, 2012 | A version of this story appeared in Volume 90, Issue 6

Credit: Courtesy of Mark Grinstaff
Credit: Courtesy of Mark Grinstaff
\
\

 

\
Credit:
\
\

 

\

The anticancer compound SN-38 releases slowly from a superhydrophobic polymeric mesh.

A superhydrophobic polymeric mesh, in which the displacement of air slows the progress of infiltrating water, has been designed as a new type of slow-release drug delivery system (J. Am. Chem. Soc., DOI: 10.1021/ja211148a). A team led by Boston University’s Mark W. Grinstaff used an electrospinning technique to create the mesh from hydroxycaproic acid, glycerol, and stearic acid. The mesh, which has an extremely high surface area and resembles a jumble of spaghetti, can be loaded with a drug. Air serves as a barrier to help control how fast water seeps through the mesh, slowing down drug release to weeks. The researchers tested the concept by loading the mesh with SN-38, the active form of the cancer drug irinotecan. They placed the loaded mesh in a soup of biologically relevant compounds, such as albumin, to see how a biological environment might affect the drug’s release rate. They then added human lung cancer cells to the mix and found that the drug killed the cancer cells slowly and continuously over several weeks.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.